cherry angioma. Hemangioma of skin and subcutaneous tissue
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: male and female clients between the ages of 20 and 65 years in general health with at least three cherry angiomas
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding a history of diseases that affect the body's wound healing ability (such as diabetes, connective tissue diseases, malnutrition, immunodeficiency, tendency to form keloids and hypertrophic scars, etc.) a history of taking certain medications that affect the wound healing process within the last 6 months (such as prednisolone, isotretinoin, immunosuppressant drugs, anticoagulant drugs, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cosmetic outcome. Timepoint: One week and four weeks after treatment. Method of measurement: Dermatoscope and Visioface digital imaging. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient-perceived pain: Pain intensity of each lesion during and immediately after treatment.Adverse effects: Occurrence of erythema, inflammation, scarring, or other side effects after treatment.Time to noticeable improvement: Duration until significant lesion improvement is observed, assessed at one- and four-week follow-up visits. Timepoint: one- and four-week after treatment. Method of measurement: Patient-perceived pain: Assessed using a questionnaire during and immediately after treatment.Adverse effects: Occurrence of erythema, inflammation, scarring, or other side effects recorded.Time to noticeable improvement: Duration until significant lesion improvement, assessed at 1- and 4-week follow-ups. | — |
Countries
Iran (Islamic Republic of)
Contacts
Iran University of Medical Sciences